A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease

International Journal of Geriatric Psychiatry

Volumn 23, Issue 2, 2008, Pages 155-160

  Connelly, Peter J ^a   Prentice, Neil P ^a   Cousland, Gary ^b   Bonham, Jim ^c  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Murray Royal Hospital   (United Kingdom)

^c SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; Cholinesterase; Folic acid; Inhibitors; Randomised placebo controlled trial

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; FOLIC ACID; GALANTAMINE; HOMOCYSTEINE; PLACEBO; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG USE; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; OUTCOMES RESEARCH; OUTPATIENT CARE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOCIAL BEHAVIOR; UNSPECIFIED SIDE EFFECT;

AGED; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; CHOLINESTERASE INHIBITORS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; FOLIC ACID; FOLIC ACID DEFICIENCY; GALANTAMINE; HOMOCYSTEINE; HUMANS; INDANS; MALE; MENTAL STATUS SCHEDULE; PHENYLCARBAMATES; PIPERIDINES; PLACEBOS; TREATMENT OUTCOME; VITAMIN B COMPLEX; VITAMINS;

EID: 39749191394     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.1856     Document Type: Article

References (31)

1. Bryan J, Calvaresi E, Hughes D. 2002. Short-term folate, vitamin B-12 or vitamin B-6 supplementation slightly affects memory performance but not mood in women of various ages. J Nutrition 132: 1345-1356.
2. Clarke R, Armitage J. 2000. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. Seminars Thromb Hemostas 26: 341-348.
3. Clarke R, Harrison G, Richards S. Vital Trial Collaborative Group. 2003. Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. J Internal Med 254: 67-75.
4. Connelly PJ, Prentice NP, Fowler KG. 2005. Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease. J Neurology Neurosurg Psychiatry 76: 320-324.
5. Durga J, van Boxtel MPJ, Schouten EJ, et al. 2007. Effect of 3-year folic acid supplementation on cognitive function in older adults it the FACIT trial: a randomised, double-blind, controleed trial. Lancet 369: 208-216.
6. Folstein MF, Folstein SE, McHugh PR. 1975. 'Mini-Mental State'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
7. Garcia A, Haron Y, Pulman K, et al. 2004. Increases in homocysteine are related to worsening of stroop scores in healthy elderly persons: a prospective follow-up study. J Gerontolog Ser A-Biologic Sci Medic Sci 59: 1323-1327.
8. Gortz P, Hoinkes A, Fleischer W, et al. 2004. Implications for hyperhomocysteinaemia: not homocysteine but its oxidised forms strongly inhibit neuronal network activity. J Neurologic Sci 218: 109-114.
9. Hanyu H, Shimizu T, Tanaka Y, et al. 2003. Regional cerebral blood flow patterns and response to donepezil treatment in patients with Alzheimer's disease. Dement Geriatr Cog Disord 15: 177-182.
10. Lipton SA. 2005. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheim Res 2: 155-165.
11. McKhann G, Drachman D, Folstein M, et al. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
12. McMahon JA, Green TJ, Skeaff CM, et al. 2006. A ontrolled trial of homocysteine lowering and cognitive performance. NE J Med 354: 2764-2772.
13. Miller AL. 2003. The methionine-homocysteine cycle and its effects on cognitive diseases. Alternat Med Rev 8: 7-19.
14. NICE. 2001. Guidance on the Use of Donepezil, Rivastigmine and Galantamine for the Treatment of Alzheimer's Disease. Nations Institute of Clinical Excellence: London.
15. NICE. 2006a. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease http://www.nice.org.uk/ page.aspx?o=288826.
16. NICE. 2006b. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (appraisal consultation). National Institute of Health and Clinical Excellence: London.
17. Nilsson K, Gustafson L, Hultberg B. 2001. Improvement of cognitive functions after cobalamin/folate supplementation in elderly patients with dementia and elevated plasma homocysteine. Int J Geriatr Psychiatry 16: 609-614.
18. Nilsson K, Gustafson L, Hultberg B. 2004. Plasma homocysteine concentration relates to the severity but not to the duration of Alzheimer's disease. Int J Geriatr Psychiatry 19: 666-672.
19. Nitsch RM, Deng M, Tennis M, et al. 2000. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurology 48: 913-918.
20. Ravaglia G, Forti P, Maioli F, et al. 2000. Elevated plasma homocysteine levels in centenarians are not associated with cognitive impairment. Mechanis Ageing Develop 121: 251-261.
21. Rosen WG, Terry RD, Fuld PA, et al. 1980. Pathological verification of ischemic score in differentiation of dementias. Ann Neurology 7: 486-488.
22. Scott TM, Tucker KL, Bhadelia A, et al. 2004. Homocysteine and B vitamins relate to brain volume and white-matter changes in geriatric patients with psychiatric disorders. Am J Geriatr Psychiatry 12: 631-638.
23. Seshadri S, Beiser A, Selhub J, et al. 2002. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. NE J Med 346: 476-483.
24. Shea TB, Lyons-Weiler J, Rogers E. 2002. Homocysteine, folate deprivation and Alzheimer neuropathology. J Alzheim Dis 4: 261-267.
25. Snowdon DA, Tully CL, Smith CD, et al. 2000. Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study. Am J Clin Nutrit 71: 993-998.
26. Sommer BR, Hoff AL, Costa M. 2003. Folic acid supplementation in dementia: a preliminary report. J Geriatr Psychiatry Neurol 16: 156-159.
27. Spiegel R, Brunner C, Ermini-Funfschilling D, et al. 1991. A new behavioral assessment scale for geriatric out- and in-patients: the NOSGER (Nurses' Observation Scale for Geriatric Patients). J Am Geriatr Soc 39: 339-347.
28. SPSS. 2001. Statistical Package for the Social Sciences (SPSS) version 11.0 for Windows. SPSS Inc: Chicago, IL.
29. Takeda A, Loveman E, Clegg A, et al. 2006. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry 21: 17-28.
30. Tariot PN, Farlow MR, Grossberg GT, et al. 2004. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. J Am Medic Assoc 291: 317-324.
31. Wecshler D. 1981. Weschler Adult Intelligence Scale - Revised. The Psychological Corporation: New York.